Veterinary Medicines

Feliserin Plus

Authorised
  • HORSE PROTEINS
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE PANLEUKOPENIA VIRUS
  • Equine serum, immunosera, antibodies against Felid herpesvirus 1
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE CALCIVIRUS 255
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE CALCIVIRUS 2024
Download as PDF

Product identification

Medicine name:
Feliserin Plus
Active substance:
  • HORSE PROTEINS
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE PANLEUKOPENIA VIRUS
  • Equine serum, immunosera, antibodies against Felid herpesvirus 1
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE CALCIVIRUS 255
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE CALCIVIRUS 2024
Target species:
  • Dog
  • Cat
Route of administration:
  • Subcutaneous use
  • Intramuscular use

Product details

Active substance and strength:
  • HORSE PROTEINS
    70.00
    serum neutralising unit(s)
    /
    1.00
    millilitre(s)
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE PANLEUKOPENIA VIRUS
    10000.00
    50% neutralisation dose
    /
    1.00
    millilitre(s)
  • Equine serum, immunosera, antibodies against Felid herpesvirus 1
    100.00
    50% neutralisation dose
    /
    1.00
    millilitre(s)
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE CALCIVIRUS 255
    10000.00
    50% neutralisation dose
    /
    1.00
    millilitre(s)
  • EQUINE SERUM, IMMUNOSERA, ANTIBODIES AGAINST FELINE CALCIVIRUS 2024
    10000.00
    50% neutralisation dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
    • Cat
  • Intramuscular use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AM01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ceva Tiergesundheit GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva Tiergesundheit (Riems) GmbH
  • IDT Biologika GmbH
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 35a/92
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 22/04/2022
Download
How useful was this page?:
Average: 2 (2 votes)
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."